[1]韦雪柔,孙春元,李晓博,等.肠愈宁方保留灌肠治疗大肠湿热型溃疡性直肠炎的疗效[J].医学信息,2021,34(19):158-161.[doi:10.3969/j.issn.1006-1959.2021.19.043]
　WEI Xue-rou,SUN Chun-yuan,LI Xiao-bo,et al.Study on the Curative Effect of Changyuning Decoction Retention Enema in the Treatmentof Large Intestine Dampness-heat Ulcerative Proctitis[J].Medical Information,2021,34(19):158-161.[doi:10.3969/j.issn.1006-1959.2021.19.043]
点击复制

肠愈宁方保留灌肠治疗大肠湿热型溃疡性直肠炎的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年19期
页码:
158-161
栏目:
中医中药
出版日期:
2021-10-01

文章信息/Info

Title:
Study on the Curative Effect of Changyuning Decoction Retention Enema in the Treatmentof Large Intestine Dampness-heat Ulcerative Proctitis
文章编号:
1006-1959（2021）19-0158-04
作者:
韦雪柔1; 孙春元2; 李晓博1; 叶九林1; 石 健1
1.安徽中医药大学第一附属医院肛肠科，安徽 合肥 230031；2.安徽中医药大学，安徽 合肥 230031
Author(s):
WEI Xue-rou1; SUN Chun-yuan2; LI Xiao-bo1; YE Jiu-lin1; SHI Jian1
1.Department of Anorectal,the First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei 230031,Anhui,China;2.Anhui University of Chinese Medicine,Hefei 230031,Anhui,China
关键词:
溃疡性直肠炎; 肠愈宁方; 美沙拉嗪栓; 保留灌肠
Keywords:
Ulcerative proctitis; Changyuning Prescription; Mesalamine; Retention enema
分类号:
R574.63
DOI:
10.3969/j.issn.1006-1959.2021.19.043
文献标志码:
A
摘要:
目的 探讨肠愈宁方保留灌肠治疗大肠湿热型溃疡性直肠炎的临床疗效。方法 采用随机数字表法将2019年8月-2020年8月就诊于安徽中医药大学第一附属医院诊断为大肠湿热型溃疡性直肠炎患者60例分为美沙拉嗪组及肠愈宁组，各30例。美沙拉嗪组给予美沙拉嗪栓纳肛治疗，肠愈宁组给予肠愈宁方保留灌肠。比较两组治疗前后中医症候积分、改良的Mayo活动指数评分、Geboes评分、血清炎性因子（CRP、IL-8、TNF-α）水平。结果 肠愈宁组治疗总有效率为93.33%，高于美沙拉嗪组的73.33%，差异有统计学意义（P＜0.05）；美沙拉嗪组治疗前后中医症候积分比较，差异无统计学意义（P＞0.05）；肠愈宁组中医症候积分低于治疗前，差异有统计学意义（P＜0.05）；两组患者改良的Mayo活动指数评分、Geboes评分、血清CRP、IL-8、TNF-α水平均低于治疗前，差异有统计学意义（P＜0.05）；治疗后肠愈宁组中医症候积分、改良的Mayo活动指数评分、Geboes评分、血清CRP、IL-8、TNF-α低于美沙拉嗪组，差异有统计学意义（P＜0.05）。结论 肠愈宁方保留灌肠可明显改善大肠湿热型溃疡性直肠炎患者的临床症状，减轻炎症反应，促进黏膜愈合，总体治疗效果优于美沙拉嗪栓。
Abstract:
Objective To explore the clinical effect of Changyuning decoction retention enema on ulcerative proctitis of large intestine damp-heat.Methods Sixty patients with ulcerative proctitis of large intestine damp-heat diagnosed in the First Affiliated Hospital of Anhui University of Chinese Medicine from August 2019 to August 2020 were randomly divided into mesalazine group and Changyuning group with 30 cases each. The mesalazine group was treated with mesalazine suppository, and Changyuning group was treated with Changyuning decoction retention enema. The TCM symptom scores， improved Mayo activity index， Geboes score and serum inflammatory factors (CRP, IL-8, TNF-α) of before and after treatment were compared between the two groups.Results The total effective rate in Changyuning group was 93.33%, which was higher than 73.33% of Mesalazine group, and the difference was statistically significant (P<0.05). Compared with before and after treatment, there was no significant difference in TCM symptom score in mesalazine group (P>0.05)， while the TCM symptom score of Changyuning group was lower than before treatment, and the difference was statistically significant (P<0.05). The improved Mayo activity index， Geboes score and serum CRP， IL-8， TNF-α were lower than before treatment, and the difference was statistically significant (P<0.05). After treatment, the TCM symptom score， improved Mayo activity index, Geboes score and serum CRP， IL-8， TNF-α in Changyuning group were lower than those in Mesalazine group, and the difference was statistically significant (P<0.05).Conclusion Changyuning decoction retention enema can obviously improve the clinical symptoms of ulcerative proctitis patients with large intestine damp-heat, reduce inflammatory reaction and promote mucosal healing, and the overall therapeutic effect is better than that of mesalazine suppository.

参考文献/References:

[1]何飞龙,金玉弟,袁金仁,等.中药保留灌肠联合离子导入治疗湿热蕴结型溃疡性直肠炎的效果观察[J].中国中医药科技,2019,26(6):904-906.[2]Gallo G,Kotze PG,Spinelli A.Surgery in ulcerative colitis: When? How?[J].Best Pract Res Clin Gastroenterol,2018(32-33):71-78.[3]Huguet JM,Ferrer-Barceló L,Suárez P,et al.Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression?[J].Scand J Gastroenterol,2018,53(10-11):1286-1290.[4]吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见(2018年,北京)[J].中华消化杂志,2018,38(5):292-311.[5]张声生,沈洪,郑凯,等.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):3585-3589.[6]徐琛.愈疡汤保留灌肠+美沙拉嗪栓塞肛对大肠湿热型直肠型溃疡性结肠炎症状改善及GIQLI评分的影响[J].江西中医药大学学报,2020,32(5):61-63.[7]张声生.溃疡性结肠炎中医诊疗共识意见[J].中华中医药杂志,2010,25(6):891-895.[8]Wehkamp J,Stange EF.Recent advances and emerging therapies in the non-surgical management of ulcerative colitis[J].F1000Res,2018(7):F1000.[9]Monif GRG.Is ulcerative colitis a disease of a dysfunctional microbiota?[J].Med Hypotheses,2019(131):109300.[10]Yu YR,Rodriguez JR.Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes[J].Semin Pediatr Surg,2017,26(6):349-355.[11]Bopanna S,Ananthakrishnan AN,Kedia S,et al.Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2017,2(4):269-276.[12]李建军.美沙拉秦栓联合布拉氏酵母菌散治疗轻中度溃疡性直肠炎疗效观察[J].现代中西医结合杂志,2020,29(20):2241-2244.[13]Wu C,Guan L,Yao L,et al.Mesalazine suppository for the treatment of refractory ulcerative chronic radiation proctitis[J].Exp Ther Med,2018,16(3):2319-2324.[14]安慧娟,白明贵.八纲辨证在《伤寒论》下利证应用[J].中医药临床杂志,2017,29(8):1172-1174.[15]高鸿亮,周禾.美沙拉嗪联合维生素D3和益生菌治疗轻中度活动期溃疡性结肠炎疗效观察[J].中华实用诊断与治疗杂志,2020,34(11):1169-1171.[16]张杨,赵悦,金宝,等.肠愈宁治疗溃疡性结肠炎的疗效研究[J].实用药物与临床,2019,22(6):613-615.[17]王海强,王瑶,李国庆,等.肠愈宁颗粒对溃疡性结肠炎大鼠部分免疫机制的影响[J].世界中医药,2020,15(17):2570-2574.[18]张冰,谢晶日,孙涛.肠愈宁对溃疡性结肠炎模型大鼠结肠黏膜损伤修复的作用研究[J].中国中西医结合消化杂志,2020,28(6):427-432.[19]朱光辉,许杨宝.肠愈宁颗粒联合美沙拉嗪治疗老年活动期溃疡性结肠炎的疗效及对血清炎症因子、免疫功能和凝血功能的影响[J].中国老年学杂志,2019,39(24):5985-5988.

更新日期/Last Update: 1900-01-01